UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically necessary ...
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized controlled trial comparing the UroLift™ System with Rezūm™ ...
Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...
Over the past decade, Teleflex has transformed from a diverse industrial, commercial, and healthcare company to one focused on single-use medical devices using the dual levers of acquisitions and ...
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) presented significant clinical findings at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas. The data from two randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback